On this page
Infliximab was the first biologic medicine used for inflammatory bowel disease (IBD) and is still one of the most widely used. It can settle a flare-up that hasn't responded to other treatment and then keep the disease quiet, often for many years.
What is it and how does it work?
Infliximab is a biologic medicine: a protein made in the laboratory. It is an antibody that blocks tumour necrosis factor (TNF), a chemical messenger that drives inflammation in Crohn's disease (CD) and ulcerative colitis (UC). Medicines that work this way are called anti-TNFs.
The original brand is Remicade. Most people in the UK are now treated with a biosimilar, a version made by another company after the patent ended. Biosimilars, such as Remsima, Inflectra, Flixabi and Zessly, work just as well and are as safe, and they cost the NHS much less, which means more people can be treated. You may be switched from one brand to another; your IBD team will tell you if this happens.
What is it used for?
- Moderate to severe CD or UC that hasn't responded to, or can't be treated with, steroids and immunosuppressants such as azathioprine.
- Crohn's disease with fistulas (abnormal channels, often around the back passage).
- A severe flare-up of UC in hospital that hasn't responded to steroids given into a vein ("rescue" treatment), to try to avoid surgery.
- Children and teenagers with CD or UC, as well as adults.
It is often given together with azathioprine, mercaptopurine or methotrexate. Taking both helps infliximab work for longer, because it reduces the chance of the body making antibodies against it.
Before you start
You will be checked for infections that infliximab could make worse:
- Tuberculosis (TB), with a blood test and usually a chest X-ray. If you have ever been exposed to TB, you may need a course of antibiotics first.
- Hepatitis B and C and HIV, with blood tests.
- Chickenpox, to see if you are immune.
Tell your team if you have heart failure, multiple sclerosis or another nerve condition, have had cancer, or have a current infection. It is a good idea to get any vaccines you need, especially live ones, before you start (see Vaccinations below).
How is it given?
As a drip (infusion) into a vein, at a hospital or infusion clinic. You usually have three starting doses, at weeks 0, 2 and 6, then a dose every 8 weeks. Each infusion takes about two hours at first, and may be shortened later. The dose depends on your weight.
As an injection under the skin. One brand (Remsima) also comes as an injection pen. People usually have their first doses by drip, then switch to injecting themselves at home every two weeks. The injections are delivered to your home by a homecare company and kept in the fridge.
Some people notice an improvement within days; for others it takes a few weeks. If it is not working well enough, your team may increase the dose or give it more often.
Drug levels and antibodies
Your team may measure the level of infliximab in your blood, usually just before a dose, and check whether your body has made antibodies against it. This helps them decide whether to change the dose, add an immunosuppressant or try a different medicine. It is one of the reasons for keeping to your appointments.
Side effects
Most people have no serious side effects, but it is important to know what to look out for.
During or soon after an infusion: some people have a reaction, such as flushing, itching, a rash, headache, feeling sick, chest tightness or breathlessness. Infusions are given where staff can treat this straight away, often by slowing the drip or giving an antihistamine. Reactions are more likely if you have had a long gap between doses.
A few days to two weeks after a dose: a delayed reaction can cause joint or muscle pain, fever, rash or swelling. Tell your IBD team.
At any time:
- Infections. Infliximab reduces your ability to fight some infections, and serious infections, including TB, can occur. Contact your team or GP promptly if you have a fever, feel unwell or have signs of infection, and tell them you take infliximab.
- Skin problems, including a rash that looks like psoriasis or eczema. This can usually be treated without stopping infliximab.
- Abnormal liver tests, found on routine blood tests.
Rarely: worsening of heart failure; inflammation of the nerves, causing numbness, tingling, weakness or problems with vision; a lupus-like illness with joint pain and rash; and allergic reactions.
Long-term risks
- Skin cancer. The risk of some skin cancers is slightly increased. Use a high-factor sunscreen, avoid sunbeds and have any new or changing patch of skin checked.
- Lymphoma. The risk of lymphoma, a cancer of the lymph glands, is slightly increased, mainly when infliximab is combined with azathioprine or mercaptopurine. The overall risk remains low, and for most people the benefits of controlling IBD outweigh it. See IBD, risk of bowel cancer and lymphoma.
Vaccinations
You should not have live vaccines while taking infliximab, or for at least three months after stopping, unless your specialist advises otherwise. These include yellow fever, oral typhoid and MMR. Non-live vaccines are safe and recommended: the yearly flu injection (not the nasal spray), COVID-19, pneumococcal and the non-live shingles vaccine.
If you have never had chickenpox and you come into contact with someone who has chickenpox or shingles, contact your GP or IBD team the same day.
Pregnancy and breastfeeding
Infliximab is not thought to harm an unborn baby, and most specialists advise continuing it during pregnancy, because an active flare-up is a greater risk to mother and baby. Your team may adjust the timing of doses late in pregnancy. Infliximab crosses the placenta, so the baby's GP, health visitor and practice nurse need to know: some live vaccines, such as BCG and rotavirus, may need to be delayed. Infliximab is considered compatible with breastfeeding.
If you are planning a pregnancy, talk to your IBD team first; see Pregnancy and Inflammatory Bowel Disease.
Surgery, dental work and travel
Tell your surgeon or dentist that you take infliximab before any operation or procedure. If you are travelling, plan your doses around the trip, and for injections, take a cool bag and a letter from your IBD team. See Travel Insurance with Crohn's or Colitis.
If infliximab does not work
If it doesn't help, or stops working, your team may change the dose, add an immunosuppressant, or switch you to another medicine, such as adalimumab, vedolizumab, ustekinumab or a newer treatment such as risankizumab or upadacitinib. See Medicines for Crohn's Disease and Ulcerative Colitis.
Never stop infliximab without discussing it with your IBD team first.